Michael Recht, MD, PhD, MBA (he/him/his)

Chief Medical and Scientific Officer
National Hemophilia Foundation
New York, New York, United States

Michael Recht MD, PhD, MBA is the Chief Medical and Scientific Officer of the National Hemophilia Foundation (NHF). As NHF's CMSO, Dr. Recht works at the strategic and policy level to inform the scientific direction of the organization. Dr. Recht works across NHF's organization to define, develop, and implement NHF's science and research strategy. In addition, Dr. Recht is a Professor of Clinical Pediatrics at the Yale Center for Bleeding and Clotting Disorders at Yale University School of Medicine. There, he sees infants, children, adolescents and young adults with inherited bleeding disorders.

Presentation(s):

• OC 20.5 - The WFH Gene Therapy Registry: A Collaborative Approach Towards a Global Resource for the Long-term Follow-up of People with Hemophilia Treated with Gene Therapy

  Sunday, June 25, 2023
  15:45 – 16:00 ET

• OC 24.2 - Estimated Factor VIII Activity Levels at the Time of Bleeding Events in Individuals with Hemophilia A without Inhibitors

  Sunday, June 25, 2023
  15:00 – 15:15 ET

• PB0191 - myGTR: a patient engagement tool from the World Federation of Hemophilia Gene Therapy Registry

  Sunday, June 25, 2023
  18:30 – 19:30 ET

• PB0229 - DESIGNING THE RYPLAZIM® (PLASMINOGEN, HUMAN-tvmh) ARM OF ATHN TRANSENDS: SAFETY AND EFFECTIVENESS IN PEOPLE WITH PLASMINOGEN DEFICIENCY

  Sunday, June 25, 2023
  18:30 – 19:30 ET

• PB0323 - Preliminary Analysis of ATHN 16: Real-World Safety of Eptacog Beta

  Sunday, June 25, 2023
  18:30 – 19:30 ET

• PB0625 - Emicizumab Prophylaxis in People with Hemophilia A Aged ≥50 Years with Comorbidities: Experience From the ATHN 7 Hemophilia Natural History Study

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB0629 - Designing the Efanesoctocog Alfa Module of ATHN Transcends: Safety, Tolerability, and Effectiveness in Previously Untreated Patients with Hemophilia A

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB0672 - Real-World data on Hemophilia A patients switching to either BAY 94-9027 or BAY 81-8973 from Emicizumab using the ATHNdataset

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB0837 - Analysis of the change in diagnosis of von Willebrand disease by region and economic status

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB0987 - Hereditary Antithrombin Deficiency Pilot Project Registry from the American Thrombosis and Hemostasis Network (ATHN)

  Monday, June 26, 2023
  18:30 – 19:30 ET

• OC 52.1 - Assessing the safety profile of AMT-060 and etranacogene dezaparvovec gene therapies across clinical trials in people with severe/moderately severe hemophilia B

  Tuesday, June 27, 2023
  10:45 – 11:00 ET

• OC 52.5 - Phase 3 HOPE-B trial of etranacogene dezaparvovec in severe/moderately severe hemophilia B: A post hoc responder analysis of participants who received full dose and responded to treatment

  Tuesday, June 27, 2023
  11:45 – 12:00 ET

• PB1241 - ATHN 11: Observational Study of Long-Term Outcomes of Liver Transplantation

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1278 - Title: Real-World data on Hemophilia A patients with inhibitors switching to either BAY 94-9027 or BAY 81-8973 in the ATHNdataset

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1291 - Joint range of motion findings among female patients with hemophilia A from the ATHNdataset

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• OC 75.1 - First US Rare Bleeding Disorder Genotype-Phenotype Registry (ATHN 10) Discovers Many Individuals with Both Novel and Multiple Variants Using a Customized 30-Gene Next-Generation Sequencing Panel

  Wednesday, June 28, 2023
  10:15 – 10:30 ET